Most importantly, the RSK inhibitor was highly effective in targeting triple-negative breast cancer and prostate carcinoma not only in vitro but also in a pre-clinical in vivo setting [31, 32, 34] and showed initial signs of efficacy in metastatic breast cancer in a Phase I clinical trial [33]. The gene discussed is RPS6KA3; the disease is triple-negative breast carcinoma.